

IPSOGEN acquires a License from Stanford University on LNK mutations

Marseille, January 17th 2011 - IPSOGEN (Alternext - FR0010626028 – ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces the signature of an agreement with Stanford University for the worldwide license on genomic mutations in the LNK gene.

Dysregulated JAK-STAT signaling due to activation of tyrosine kinases is a common feature of myeloproliferative neoplasms (MPNs). The lymphocyte specific adaptor protein (LNK) is a negative regulator of the JAK-STAT signaling pathway, and its disruption could represent an alternative mechanism to JAK2 or MPL mutations in the pathobiology of MPN. The first disease-related mutations of LNK in patients with JAK2 V617F- negative MPNs were reported by S. Oh et al. at Stanford University, Cal, US in Blood in April 2010. Additional findings on the potential role of the LNK protein to identify predisposition to develop leukemia in MPN patients have been reported in a recent publication in Leukemia (Pardanani et al, 2010). Based on these findings, IPSOGEN aims at developing diagnostic tools that could be used by diagnostic laboratories in their routine practice.

IPSOGEN’s CEO, Vincent Fert stated: *“The LNK mutation will complement our MPN biomarkers portfolio, including the JAK2 V617F mutation, for the management of myeloid disorders. It could provide additional essential information to physicians and patients about the nature of these diseases. This agreement, established with a renowned university involved in world-class cancer research and care, exemplifies IPSOGEN strategy of building value on key biological science to improve cancer patients’ management”.*

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, Ipsogen intends to become a world leader in the molecular profiling of cancers and to pursue the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

At June 2010 Ipsogen employed 70 people. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in Stamford, CT, USA.

For further information, visit www.ipsogen.com

Contacts

<p>IPSOGEN</p> <p>Vincent Fert</p> <p>CEO Tel.: +33 (0)4 9129 3090 fert@ipsogen.com</p> <p>Pascale Boissel</p> <p>CFO Tel.: + 33 (0)4 9129 3090 Pascale.boissel@ipsogen.com</p>	<p>ATCG Partners</p> <p>Corporate and product information</p> <p>Marielle Bricman Tel : 33 (0)4 91 25 07 85 ipsogen@atcg-partners.com</p>	<p>NewCap.</p> <p>Financial communication and Investor relations</p> <p>Axelle Vuillermet & Pierre Laurent Tel.: +33 (0)1 44 71 94 93 ipsogen@newcap.fr</p>
---	--	--

